Merger Opportunities Sesen Bio has recently undergone mergers and partnerships with companies like Carisma Therapeutics Inc and Roche, signifying potential collaboration and sales opportunities to explore joint offerings or cross-selling strategies with the merged entities.
Personnel Expansion With recent key hires for positions like Director of Finance and Senior Director of Global Drug Safety, Sesen Bio is strengthening its team to drive growth, presenting a potential opportunity for service providers to offer solutions that support the company's expanding workforce and operations.
Financial Investigation Weiss Law investigating possible violations of law by Sesen Bio's board of directors indicates a need for legal or financial advisory services. Sales professionals in these sectors could explore offering compliance or due diligence solutions to enhance corporate governance.
Acquisition Alert The acquisition of Sesen Bio by Carisma Therapeutics Inc for $189 million opens up opportunities for business development professionals to engage with the acquiring company, identify synergies, and offer products or services to support the post-acquisition integration process.
Clinical Partnership Sesen Bio's collaboration with Roche, where they sold patent rights for a significant payment, indicates a focus on research and development. This presents an opportunity for suppliers of laboratory equipment, research tools, or scientific services to engage with the company for potential sales deals.
Sesen Bio uses 8 technology products and services including SiteCatalyst, cdnjs, Twitter Emoji (Twemoji), and more. Explore Sesen Bio's tech stack below.
| Sesen Bio Email Formats | Percentage |
| First.Last@sesenbio.com | 50% |
| First.Last@sesenbio.com | 50% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
We are passionate in our commitment to save and improve the lives of patients. Sesen Bio is a late-stage company developing fusion protein medicines for the treatment of patients with cancer. In February 2021, the FDA accepted for filing the Company’s BLA for Vicineum™, a potential best-in-class treatment for non-muscle invasive bladder cancer.
Company Overview
Media & News
Funding & FinancialsFunding & Financials
1-888-653-2347 
support@leadiq.com